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The identification of the cofactors required for HIV-1
entry into cells promises to provide new insights into
viral transmission and pathogenesis, and opens new
avenues for AIDS therapy and prophylaxis.
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The entry pathway of the human immunodeficiency virus
type-1 (HIV-1) can be divided into three major events:
binding, activation and fusion. The viral envelope protein
is essential for each of these stages; it consists of a surface
subunit, gp120, and a transmembrane subunit, gp41,
which form an oligomeric complex in the virion membrane
[1]. The gp120 subunit contains a binding domain specific
for the human CD4 molecule, the cellular receptor for
HIV-1. The gp41 subunit contains a fusogenic hydropho-
bic peptide at its amino terminus, which is essential for
fusion of the viral and cellular membranes. The primary
cell types infected by HIV — helper T cells, macrophages
and dendritic cells — all express CD4, which is thus a fun-
damental determinant of both the species and cellular
tropism of HIV-1. The CD4–gp120 interaction is thought
to activate the fusion activity of the envelope oligomer by
inducing a conformation shift [2,3] that exposes new func-
tional domains, such as the third variable region (V3) of
gp120. The consequent fusion of the viral and plasma
membranes releases the viral core into the cell to initiate
replication. The CD4–gp120 interaction is thus important
for the first two major steps in the HIV entry pathway; it
provides a high affinity binding receptor and is involved in
activating the fusion activity of the viral envelope.
Soon after CD4 was identified as the cellular receptor for
HIV-1, it became clear that expression of CD4 alone is
insufficient for envelope-mediated fusion to occur. One
test of this is to transfect a cell line with the CD4 gene,
and see if it confers the ability to fuse with cells express-
ing the HIV-1 gp120 protein. A small number of human
cell lines, and the vast majority of non-human cell lines,
fail this test [4,5]; the human cell lines that fail are
classed as ‘restrictive’, as opposed to the ‘permissive’ cell
lines that pass the test when they express CD4. The
restrictive CD4+ cells were also found to resist infection
by cell-free virus particles, as a result of a block at the
level of virus entry [6–8]. The fusion defect of the restric-
tive CD4+ cells can, however, be complemented by prior
fusion with permissive CD4– cells, indicating that the
block to fusion is the result of the lack of a cofactor in
some cell types [9–11].
The expression of different fusion cofactors by various
cell types has been shown to be a major determinant of
HIV-1 tropism [12]. The tropism of different HIV-1
strains is primarily distinguished on the basis of their
ability to infect monocyte-derived macrophages as
opposed to established T-cell lines. Macrophage-tropic
viruses are thought to be fundamental for the transmission
and pathogenesis of HIV-1; for example, macrophage-
tropic viruses have been shown to predominate early in
infection, possibly as a result of selection during transmis-
sion when the initial cellular targets of an infection are
tissue macrophages or dendritic cells. Macrophages are
also believed to facilitate the dissemination of virus to
various tissues within an infected individual, and thereby
to contribute to the pathological course of the infection.
On the virus side, important determinants of tropism have
been mapped to the V3 region of gp120 [13]. Until
recently, the cellular determinants of tropism were not
known, but several different fusion cofactors have now
been identified and established as the cellular basis for
the specificity of the fusion reaction [14–20].
The first fusion cofactor to be identified was specific for
virus strains adapted to T-cell lines [14], and proved to be
a member of the seven transmembrane G-protein-coupled
receptor superfamily. Several laboratories investigating
that superfamily had previously isolated cDNAs for the
same receptor, but had been unable to determine its
ligand. Because of its role as a fusion cofactor, the protein
has been dubbed ‘fusin’, but this may be a temporary
appellation pending identification of its natural ligand.
Sequence analysis shows that fusin has ~35 % sequence
similarity to interleukin 8 (IL-8) receptor-b, and so is likely
to be the receptor for an as yet undefined chemokine. As
expected, fusin was found to be required for cell fusion
mediated by the envelope protein of laboratory-adapted
isolates. In addition, expression of fusin on non-permissive
cell types allowed infection by cell free T-cell-tropic
viruses, but not by macrophage-tropic isolates [14].
The discovery that fusin is related to chemokine recep-
tors provided the catalyst for a dramatic convergence
between studies of HIV-1 tropism and cell entry and
investigations into the nature of antiviral factors released
by CD8 (cytotoxic) T cells. Before the discovery of fusin,
three b-chemokines — RANTES, MIP-1a and MIP-1b
— had been shown to have anti-viral activity [15]. Follow-
ing this lead, the receptors for other chemokines were
screened for their ability to act as cofactors for viral entry.
Thus, CC-CK5, a b-chemokine receptor specific for
RANTES, MIP-1a and MIP-1b, was shown to be a fusion
cofactor for macrophage-tropic viral isolates [16–18]. Fur-
thermore, the same three b-chemokines were found to
block envelope-induced fusion mediated by CC-CKR5
but not by fusin. Additional chemokine receptors, CC-
CKR2b and CC-CKR3, can also be used as cofactors by
some HIV-1 isolates [19,20] and by HIV-2 (Mark Marsh,
personal communication).
Although the potential role that these additional cofactors
play in vivo during an infection remains to be determined,
compelling evidence for the importance of CC-CKR5 in
vivo has been reported very recently [21,22]. Individuals
possessing HIV-1-resistant CD4 T cells have been identi-
fied because they have remained seronegative for HIV-1
despite having a high risk of infection [23]. The genetic
basis for their resistance to HIV-1 has now been shown to
be due to the disruption of both of their CKR5 alleles by 
a short deletion [21]. Even individuals heterozygous for
the mutation in CKR5 appear to be partially resistant to
infection [22], due either to an inhibitory effect of the
mutation or decreased expression of functional CC-
CKR5. The finding that a mutation in CKR5 renders indi-
viduals resistant to infection underscores the importance
of the interaction of macrophage-tropic viruses with the
CC-CKR5 cofactor during HIV-1 transmission. Conse-
quently, the development of agents that block the inter-
action with CC-CKR5 is a new and promising approach to
HIV-1 prophylaxis
The finding that various subsets of fusion cofactors are used
by different viral isolates provides a satisfying explanation
for the complex tropism patterns exhibited by HIV-1.
Indeed, the established tropisms of many viral strains indi-
cate that more fusion cofactors remain to be identified.
The identification of new cofactors will also be facilitated
by the development of neutralizing monoclonal antibodies
against existing cofactors; for example, a neutralizing mon-
oclonal antibody against fusin blocks HIV-1 infection of
some T-cell lines but not others, suggesting that some
T-cell lines may express additional, undefined cofactors
(Jim Hoxie and Paul Clapham, personal communication).
The mechanism by which cofactors facilitate fusion will
now be the focus of considerable investigation, for under-
standing the exact role played by chemokine receptors
during virus entry will assist their exploitation as potential
therapeutic targets. As predicted from tropism studies, the
gp120 V3 loop is an important determinant of cofactor
usage [19], and consequently also of susceptability to viral
suppression by chemokines [23]. It is interesting to note
that other retroviruses, such as murine leukaemia virus
(MLV), use cellular receptors that, like chemokine recep-
tors, have small extracellular domains [1]. In the case of
HIV-1, therefore, it might be that binding to a long rod-
like molecule, such as CD4, provides an efficient receptor
for adsorption, but that binding to a cofactor close to the
lipid bilayer is required for the subsequent events leading
to membrane fusion. One challenge now will be to under-
stand how the conformational changes induced by consec-
utive gp120 binding to its two receptors trigger gp41 to
mediate the final fusion event (Fig. 1).
An additional and provocative possibility is that binding by
gp120 V3 region to the fusion cofactor transduces a signal
to the target cell via the G-protein-coupled pathway. A
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The HIV-1 cell-entry pathway. Specific binding of CD4 by gp120
triggers a cascade of interactions that result in virus entry. CD4
binding induces a conformational shift in gp120 which is followed
by binding to a specific cofactor, determined by the V3 region of
gp120. Only after binding to the cofactor does the fusion of viral
and cellular membranes occur, mediated by insertion into the cell
membrane of the fusogenic peptide at the amino terminus of
gp41. The precise mechanism by which cofactor binding to
gp120 leads to activation of gp41 is not known but, as gp120 is
thought to occlude the fusion peptide in gp41, it is likely to involve
additional conformational changes that lead to the dissociation of
gp41 and gp120.
stimulatory signal generated during entry could possibly
play a role in the infection of non-proliferating cells such
as macrophages. Another possibility is that a signal trans-
duced during entry could induce newly infected dendritic
cells to migrate, or express cell-surface molecules enhanc-
ing their retention by proximal lymph nodes. A more thor-
ough understanding of the mechanism of fusion is also
required to explain the differences between cell–cell
fusion and cell-free infection that have been described.
For example, macrophages express fusin and also support
syncytia formation with cells infected with T-cell-tropic
HIV-1 isolates, but entry of the same viral isolates is
blocked in macrophages [24].
Understanding the entry process has important
implications for our understanding of several key aspects
of HIV-1 transmission and pathogenesis. It has also
opened up new avenues for therapeutic intervention and
prophylaxis. Several uninfected high-risk individuals have
been shown to have elevated levels of b-chemokines, sug-
gesting that b-chemokines may provide protection against
infection [23]. In light of this finding, the induction of pro-
tracted b-chemokine production could become an aim of
vaccine design. The development of new small animal
models for HIV-1 infection is another goal made feasible
by the identification of fusion cofactors. But it remains to
be seen whether creating transgenic animals expressing a
selected few cofactors will produce a satisfactory model for
a virus infection which in the natural host probably
involves many cofactors. Nevertheless, the recent discov-
eries of crucial cofactors for HIV-1 entry into cells clearly
promise to open many more doors to an increased under-
standing of HIV biology.
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